In similar studies involving CD4+ T cell depletion using the GK1.5 mAb, there was no change in protection provided against tumor growth by the EO771 WCV suggesting a limited role of CD4+ T cells in this particular anticancer vaccine (Supplementary Figure S1). The gene discussed is CD4; the disease is neoplasm.